BioWorld

Oct. 29, 2002

View Archived Issues

Dendreon Gets OK To Resume Enrollment In Phase III Study

Following a six-month delay, Dendreon Corp. received FDA clearance to resume enrollment in its second Phase III trial of Provenge, a therapeutic vaccine for hormone-resistant prostate cancer patients. (BioWorld Today) Read More

Peninsula Raises $22.1M To Fund In-Licensing Program

Read More

NIH Scientists Report Finding New Deafness Gene, Mucolipin By Name, Joining Worldwide Panoply Of Same

Read More

Abbott's Humira Continues To Impress In RA Treatment

Read More

Other News To Note

Read More

Correction

Read More

Endo's Second Phase III For MorphiDex Misses Endpoint

Read More

Aphton Reports Phase III Results Showing G17DT Extends Survival

Read More